Loading stock data…
$12.43+0.02 (+0.12%)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SELLAS Life Sciences Group, Inc. in the Healthcare sector is trading at $12.43 with a market capitalization of $2.8B. Wall Street consensus targets $32.50 (2 analysts), implying a +161.6% move over the next 12 months. The stock is currently 22% below its 52-week high of $15.88, remaining 52.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.63M↓ | -$9.25M↓ | -$8.26M↓ | -$7.08M↓ | -$6.87M |
| Net Income | -$9.61M↓ | -$8.41M↓ | -$7.66M↓ | -$6.79M↓ | -$6.60M |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...